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ABSTRACT 
BLM has key roles in homologous recombination repair, telomere maintenance and DNA 
replication. Germ-line mutation in the BLM gene causes Bloom’s syndrome, a rare disorder 
characterised by premature aging and predisposition to multiple cancers including breast 
cancer. The clinicopathological significance of BLM in sporadic breast cancers is unknown. 
We investigated BLM mRNA expression in the Molecular Taxonomy of Breast Cancer 
International Consortium cohort (n=1950) and validated in an external dataset of 2413 
tumours.  BLM protein level was evaluated in the Nottingham Tenovus series comprising 
1650 breast tumours. High BLM mRNA expression was highly significantly associated with  
high histological grade, larger tumour size, ER negative, PgR negative and triple negative 
phenotypes (ps<0.0001). High BLM mRNA expression was also linked to aggressive 
molecular phenotypes including PAM50.Her2 (p<0.0001), PAM50.Basal (p<0.0001) and 
PAM50.LumB (p<0.0001) and Genufu subtype (ER+/Her2-/High proliferation) (p<0.0001). 
PAM50.LumA tumours and Genufu subtype (ER+/Her2-/low proliferation) were more likely 
to express low levels of BLM mRNA (ps<0.0001). Integrative molecular clusters (intClust) 
intClust.1 (p<0.0001), intClust.5 (p<0.0001), intClust.9 (p<0.0001) and intClust.10 
(p<0.0001) were also more likely in tumours with high BLM mRNA expression. High BLM 
mRNA expression was associated with poor breast cancer specific survival (BCSS) 
(ps<0.000001). At the protein level, altered sub-cellular localisation with high cytoplasmic 
BLM and low nuclear BLM was linked to aggressive phenotypes. In multivariate analysis, 
BLM mRNA and BLM protein levels independently influenced BCSS (p=0.03). This is the 
first and the largest study to provide evidence that BLM is a promising biomarker in breast 
cancer.  
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INTRODUCTION 
 
Blooms syndrome helicase (BLM) is a key member of the RecQ family of DNA helicases 
and essential for the maintenance of genomic stability. BLM is an ATP-dependent 3’-5’ DNA 
helicase involved in unwinding a variety of DNA substrates that can arise during DNA 
replication and repair (1-5).  BLM has important roles in the initiation and regulation of 
homologous recombination (HR) repair of DSB (double-strand breaks). In addition, BLM is 
required for Holliday junction dissolution during the terminal stages of HR. To accomplish its 
various biological functions, BLM interacts with several DNA repair factors including 
topoisomerase III, hRMI1, hRMI1 and Rad51. BLM is also part of the BRCA1-associated 
genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, 
ATM, PMS2, the RAD50-MRE11-NBS1 protein complex and BLM (6). In addition to its 
DNA repair function, BLM is involved in the processing of stalled replication forks during 
replication and in telomere maintenance in cells (1-5). 
 
Bloom’s syndrome (BS) is a rare disorder caused by germ-line mutation in the BLM gene. BS 
is characterised by cancer predisposition, growth retardation, immunodeficiency, sunlight 
hypersensitivity and impaired fertility (7). BLM germ-line mutation results in dramatic 
reduction in BLM mRNA levels and BLM protein expression leading to extensive 
chromosomal instability manifested classically as excessive frequency of sister chromatid 
exchanges (SCEs) in BS cells (1-5).  BS patients are prone to develop leukemia, lymphomas 
and to a variety of epithelial cancers including breast cancers (7). Interestingly, 
polymorphisms in the BLM gene has been associated with increased risk of development of 
sporadic breast cancers (8).  In preclinical models, depletion of BLM by shRNA not only 
reduced proliferation in cells (9) but also sensitized to chemotherapeutic agents such as 
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camptothecins, cisplatin, 5-fluoruracil and hydroxyurea treatment (1-5, 7). BLM is an 
attractive anti-cancer drug target and small molecule inhibitors of BLM are currently under 
pre-clinical development (10). However, target validation studies including prognostic and/or 
predictive significance of BLM in human sporadic tumours have not been reported and 
therefore remain largely unknown. We hypothesised that BLM may be dysregulated in 
sporadic breast cancers and influence clinical outcomes in patient. Here in we present the first 
and the largest comprehensive study providing compelling evidence that altered BLM 
expression has prognostic and predictive significance in patients. Our data suggest that BLM 
is a rational target in breast cancer. 
 
MATERIALS AND METHODS 
BLM gene expression: METABRIC (Molecular Taxonomy of Breast Cancer International 
Consortium) cohort was evaluated for BLM gene expression. The METABRIC study 
protocol, detailing the molecular profiling methodology in a cohort of 1980 breast cancer 
samples is described by Curtis et al (11).  Patient demographics are summarized in 
supplementary Table S1 of supporting information. ER positive and/or lymphnode negative 
patients did not receive adjuvant chemotherapy.  ER negative and/or lymphnode positive 
patients received adjuvant chemotherapy.  RNA was extracted from fresh frozen tumours and 
subjected to transcriptional profiling on the Illumina HT-12 v3 platform.  The data was pre-
processed and normalized as described previously (11). BLM expression was investigated in 
this data set (BLM probe id: ILM_1709484). The Chi-square test was used for testing 
association between categorical variables and a multivariate Cox model was fitted to the data 
using as endpoint breast cancer specific death. Recursive partitioning  was used to identify a 
cut-off in gene expression values such that the resulting subgroups have significantly 
different survival courses. 
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The external validation was done using bc-GenExMiner v3.0 (Breast Cancer Gene-
Expression Miner v3.0) online dataset (http://bcgenex.centregauducheau.fr) comprising 
previously published gene expression datasets from fifteen independent breast cancer studies 
totalling 2413 tumours  and summarized in supplementary Table S2. The bioinformatics tool 
is composed of two statistical mining modules. The first module is a "prognostic module", 
which offers the possibility to evaluate the in vivo prognostic informativity of genes of 
interest in breast cancer, and the second module is a "correlation module", which permits to 
compute correlation coefficients between gene expressions or to find lists of correlated genes 
in breast cancer. We used the prognostic module in this external validation. Statistical 
analyses were performed by means of survival statistical tests (Cox model, Kaplan–Meier 
and Forest plots). Supplementary Table S2 summarizes individual cohorts where BLM 
mRNA expression was investigated.                                                                                                                     
BLM protein expression in breast cancer: The study was performed in a consecutive series 
of 1650 patients with primary invasive breast carcinomas who were diagnosed between 1986 
and 1999 and entered into the Nottingham Tenovus Primary Breast Carcinoma series.  Patient 
demographics are summarised in Supplementary Table S3. This is a well-characterized series 
of patients with long-term follow-up that have been investigated in a wide range of biomarker 
studies (12-20).  All patients were treated in a uniform way in a single institution with 
standard surgery (mastectomy or wide local excision) with radiotherapy. Prior to 1989, 
patients did not receive systemic adjuvant treatment (AT). After 1989, AT was scheduled 
based on prognostic and predictive factor status, including Nottingham Prognostic Index 
(NPI), oestrogen receptor-α (ER-α) status, and menopausal status. Patients with NPI scores of 
<3.4 (low risk) did not receive AT. In pre-menopausal patients with NPI scores of ≥3.4 (high 
risk), classical Cyclophosphamide, Methotrexate, and 5-Flurouracil (CMF) chemotherapy 
was given; patients with ER-α positive tumours were also offered endocrine therapy. 
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Postmenopausal patients with NPI scores of ≥3.4 and ER-α positivity were offered endocrine 
therapy, while ER-α negative patients received classical CMF chemotherapy. Median follow 
up was 111 months (range 1 to 233 months).  Survival data, including overall survival, 
disease-free survival (DFS), and development of loco-regional and distant metastases (DM), 
was maintained on a prospective basis.  DFS was defined as the number of months from 
diagnosis to the occurrence of local recurrence, local lymph node (LN) relapse or DM 
relapse.  Breast cancer specific survival (BCSS) was defined as the number of months from 
diagnosis to the occurrence of BC related-death. Local recurrence free survival (LRS) was 
defined the number of months from diagnosis to the occurrence of local recurrence. DM-free 
survival was defined as the number of months from diagnosis to the occurrence of DM 
relapse.  Survival was censored if the patient was still alive at the time of analysis, lost to 
follow-up, or died from other causes. 
Tumor Marker Prognostic Studies (REMARK) criteria, recommended by McShane et al (21), 
were followed throughout this study.  Ethical approval was obtained from the Nottingham 
Research Ethics Committee (C202313).  
Tissue Microarrays (TMAs) and immunohistochemistry (IHC): Tumours were arrayed in 
tissue microarrays (TMAs) constructed with 2 replicate 0.6mm cores from the centre and 
periphery of the tumours. The TMAs were immunohistochemically profiled for BLM and 
other biological antibodies (Supplementary Table S4) as previously described (12-20).  
Immunohistochemical staining was performed using the Thermo Scientific Shandon 
Sequenza chamber system (REF: 72110017), in combination with the Novolink Max Polymer 
Detection System (RE7280-K: 1250 tests), and the Leica Bond Primary Antibody Diluent 
(AR9352), each used according to the manufacturer’s instructions (Leica Microsystems).  
The tissue slides were deparaffinised with xylene and then rehydrated through five decreasing 
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concentrations of alcohol (100%, 90%, 70%, 50% and 30%) for two minutes each. Pre-
treatment antigen retrieval was performed on the TMA sections using sodium citrate buffer 
(pH 6.0) and heated for 20 minutes at 950C in a microwave (Whirpool JT359 Jet Chef 
1000W). A set of slides were incubated for 18 hours with the primary anti-BLM antibody 
(NBP1-89929, Novus Biologicals, UK), at a dilution of 1:100. Negative and positive (by 
omission of the primary antibody and IgG-matched serum) controls were included in each 
run. The negative control ensured that all the staining was produced from the specific 
interaction between antibody and antigen. 
 
Evaluation of immune staining: The tumour cores were evaluated by two scorers (TAF and 
AA) and the concordance between the two scorer was excellent (k = 0.79). Whole field 
inspection of the core was scored and intensities of nuclear staining were grouped as follows: 
0 = no staining, 1 = weak staining, 2 = moderate staining, 3 = strong staining. The percentage 
of each category was estimated (0-100%).  H-score (range 0-300) was calculated by 
multiplying intensity of staining and percentage staining. A median H score of ≥ 50 was 
taken as the cut-off for high BLM nuclear and cytoplasm expression. Not all cores within the 
TMA were suitable for IHC analysis as some cores were missing or lacked tumour (<15% 
tumour).  
Statistical analysis: Data analysis was performed using SPSS (SPSS, version 17 Chicago, 
IL). Where appropriate, Pearson’s Chi-square, Fisher’s exact, Student’s t and ANOVA one 
way tests were used. Cumulative survival probabilities were estimated using the Kaplan–
Meier method, and differences between survival rates were tested for significance using the 
log-rank test. Multivariate analysis for survival was performed using the Cox proportional 
hazard model. The proportional hazards assumption was tested using standard log-log plots. 
Hazard ratios (HR) and 95% confidence intervals (95% CI) were estimated for each variable. 
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All tests were two-sided with a 95% CI and a p value < 0.05 considered significant.  For 
multiple comparisons, p values were adjusted according to Benjamini-Hochberg method (22).  
 
Breast cancer cell lines and culture: MCF-7 (ER+/PR+/HER2-, BRCA1 proficient), MDA-
MB-231 (ER-/PR-/HER2-, BRCA1 proficient), MDA-MB-468 (ER-/PR-/HER2-, BRCA1 
proficient)  and MDA-MB-436 (ER-/PR-/HER2-, BRCA1 deficient) were purchased from 
ATCC and were grown in RPMI (MCF-7, MDA-MB-231) or DMEM (MDA-MB-468 and 
MDA-MB-436) medium with the addition of 10% foetal bovine serum and 1% 
penicillin/streptomycin. Cell lysates were prepared and Western blot analysis performed.  
Primary anti-BLM antibody (NBP1-89929, Novus Biologicals, and UK) was incubated over 
night at room temperature at a dilution of 1:1500. Primary anti-β actin antibody (1:10000 
dilution [Abcam]) was used as a loading control. Infrared dye-labelled secondary antibodies 
(Li-Cor) [IRDye 800CW Mouse Anti-Rabbit IgG and IRDye 680CW Rabbit Anti-Mouse 
IgG] were incubated at a dilution of 1:10000 for 1 hour.  Membranes were scanned with a Li-
Cor Odyssey machine (700 and 800nm) to determine protein expression.  
 
Quantitative real –time PCR: Total RNA was extracted from MCF-7, MDA-MB-231, 
MDA-MB-468 and MDA-MB-436 cells using RNeasy Mini kit (QIAGEN, UK). The 
quantification of the extracted RNA was done using a  NanoDrop 2000c Spectrophotometer 
(Thermo Scientific, UK). The cDNA was synthesized from 0.5 μg of total RNA using RT2 
first strand kit (QIAGEN, UK). qPCR was performed using SYBR Green PCR Master mix 
(applied biosystems,Warrington,UK) with primer set (BLM QuantiTect Prier Assay,Cat. No. 
QT00027671, QIAGEN) targeting BLM gene. RECQL5 mRNA level was also quantified. 
The glyceraldehyde-3-phosphate dehydrogenase housekeeper gene was used as an internal 
control (GAPDH QuantiTect Prier Assay, Cat. No. QT00079247, QIAGEN). The real-time 
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PCR for each RNA sample was performed in triplicate. NTC (No Template Control) was 
used to rule out cross contamination of reagents and surfaces. NTC included all the RT-PCR 
reagents except the RNA template. Minus reverse transcriptase (- RT) control was used to 
rule out genomic DNA contamination. 
 
RESULTS 
 
High BLM transcript levels correlate to aggressive breast cancer 
 
BLM mRNA level was investigated in the METABRIC (Molecular Taxonomy of Breast 
Cancer International Consortium) cohort comprising 1980 breast tumours. High BLM mRNA 
expression was highly significantly associated with aggressive clinicopathological features 
(Table 1) including  high histological grade, larger tumour size, high-risk Nottingham 
prognostic index (NPI  >3.4), Her-2 over expression, ER negative, PgR negative and triple 
negative phenotypes (ps<0.0001). High BLM mRNA expression was also found to be 
significantly associated with previously described molecular phenotypes in breast cancer: 
PAM50.Her2 (p<0.0001), PAM50.Basal (p<0.0001) and PAM50.LumB (p<0.0001), Genufu 
subtype (ER-/Her2-), Genufu subtype (ER+/Her2-/High proliferation) and Genufu subtype 
(Her2 positive) breast tumours. However, PAM50.LumA tumours and Genufu subtype 
(ER+/Her2-/low proliferation) were more likely to express low levels of BLM mRNA 
(ps<0.0001). Similarly, BLM mRNA level was significantly associated with the various 
biological subgroups [labelled integrative clusters (intClust) 1-10] described in the 
METABRIC study which was based on gene copy number changes and gene expression data 
(11).   High BLM mRNA expression was significantly associated with intClust.1 (p<0.0001), 
intClust.5 (p<0.0001), intClust.9 (p<0.0001) and intClust.10 (p<0.0001), which had the worst 
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clinical outcome in the METABRIC study (11).  Low BLM mRNA expression was associated 
with intClust.3 (p<0.0001), intClust.4 (p<0.0001), intClust.7 (p=0.003) and intClust.8 
(p<0.0001), which had intermediate to good prognosis in the METABRIC study (11).  
 
We then proceeded to survival analysis. High BLM mRNA expression in tumours was 
associated with adverse breast cancer specific survival (BCSS) in the whole cohort 
(p<0.0001) (Figure 1A). In ER+ sub-group, high BLM mRNA expression was associated with 
poor BCSS (p<0.0001) (Figure 1B). In the ER+ sub-group that received adjuvant endocrine 
therapy, high BLM mRNA expression remains associated with poor BCSS (p<0.0001) 
(Figure 1D).    In ER- sub-group, low BLM mRNA expression was associated with poor 
BCSS with borderline significance (p=0.049) (Figure 1C). In the ER- sub-group that received 
adjuvant chemotherapy, BLM mRNA expression did not significantly influence outcome 
(p=0.062) (Figure 1E). In multivariate Cox regression analysis that included other validated 
prognostic factors, such as lymph node stage, histological grade and tumour size ,  BLM  
mRNA expression was a powerful independent predictor for breast cancer specific survival 
(p<0.00001) (Table 2). External validation was performed using bc-GenExMiner v3.0 (Breast 
Cancer Gene-Expression Miner v3.0) online dataset (http://bcgenex.centregauducheau.fr) 
comprising previously published gene expression datasets from fifteen independent breast 
cancer studies totalling 2413 tumours and summarized in supplementary materials and Table 
S2. The dataset provides information on metastasis relapse (MR) free survival data. As 
shown in the Forest plot (Supplementary Figure S1) low BLM mRNA expression was 
significantly associated with better MR free survival Supplementary Figure S1A and S1B). 
Taken together, the data provides the first compelling evidence that high BLM mRNA 
expression has prognostic and/or predictive significance in breast cancer.  
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Altered sub-cellular localisation of BLM protein is associated with aggressive breast 
cancer 
 
BLM is a 1417 amino acid protein with a highly conserved centrally located helicase domain. 
In addition, BLM has multiple domains involved in DNA- binding, ATPase activity and 
interaction with other binding partners. The nuclear localisation signal is present in the C-
terminal region of the protein (1-5). BLM is primarily expressed in late S/G2 phase of the cell 
cycle. Upon DNA damage BLM localises to the nucleus where it interacts with Rad51 and is 
intimately involved in HR repair that is operational during the S-phase of the cell cycle (23). 
In addition, BLM undergoes post translational modifications such as phosphorylation and 
SUMOylation that can affect intracellular localisation and biochemical activity (1-5). We 
proceeded to evaluation of BLM protein expression in breast cancers. We initially profiled a 
panel of breast cancer cell lines. As shown in Supplementary Figure S2A; MDA-MB-231, 
MDA-MB-436 and MDA-MB-468 breast cancer cells have robust expression of BLM 
protein. In contrast, MCF-7 has low BLM expression. At the mRNA level, BLM is highly 
expressed in MDA-MB-231 cells compared to MCF-7, MDA-MB-436 and MDA-MB-468 
cells. The data demonstrates differential BLM expression across different breast cancer cell 
lines. We then conducted immunohistochemical evaluation of BLM protein expression in the 
Nottingham Tenovus series comprising 1650 breast tumours. Surprisingly, we observed 
complex sub-cellular localization of BLM protein in breast cancers including tumours 
exhibiting nuclear staining only, cytoplasmic staining only, nuclear-cytoplasmic co-
expression or negative staining.  
 
Nuclear BLM protein level and breast cancer: Low nuclear BLM level was seen in 54% of 
tumours (n= 682/1253) and high nuclear BLM level was observed in 46% of tumours (n= 
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571/1253) (Supplementary Figure S2B). As shown in supplementary table S5, low nuclear 
BLM level was significantly associated with larger tumours, high tumour grade, higher 
mitotic index, pleomorphism and tumour type (p<0.05). ER-, PR-, AR-, triple negative and 
basal-like phenotypes were more common in tumours with low nuclear BLM protein level 
(p<0.01). BRCA1 negative, low XRCC1, low FEN1, low SMUG1, low APE1, low Polβ, low 
ATR and low DNA-PKcs were significantly associated with tumours that have low nuclear 
BLM protein level. In addition, high p16, low p21, high MIB1, p53 mutants, low Bcl-2, low 
Top2A, low nuclear pCHEK1 and low nuclear Chk2 were more common in tumours with 
low nuclear BLM protein level (p<0.05). 
 
Cytoplasmic BLM protein level and breast cancer: High cytoplasmic BLM level was seen 
in 53% of tumours (n= 642/1212) and low cytoplasmic BLM level was seen in 47% of 
tumours (n= 570/1212) (Supplementary Figure S2B). As shown in supplementary table S6, 
high cytoplasmic BLM level was significantly associated with pleomorphism, tumour type, 
high XRCC1, high FEN1, high APE1, high ATR, high DNA-PKcs, high MIB1, high Chk2, 
high Bax levels.   
 
Nuclear and cytoplasmic co-expression of BLM in breast cancer: 28% (333/1253) were 
low nuclear/high cytoplasmic, 26.5% (332/1253) were low nuclear/low cytoplasmic, 26.5% 
(333/1253) were high nuclear/high cytoplasmic and 19% (238/1253) were high nuclear/low 
cytoplasmic (Supplementary Figure S2B).  As shown in Table 3, tumours with high 
cytoplasmic/low nuclear BLM levels were more likely to be high grade, high mitotic index, 
pleomorphism, IDC-NST tumour type, PR-, triple negative and basal-like phenotype tumours 
(p<0.0001). High p16, low p21, high MIB1, p53 mutants and high Bax levels more common 
in tumours with high cytoplasmic/low nuclear BLM levels. Interestingly, low 
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cytoplasmic/low nuclear BLM tumours were more likely to manifest low DNA repair levels 
including BRCA1 negative, low XRCC1, low FEN1, low SMUG1, low APE1, low polβ, low 
ATR and low DNA-PKcs expression.   
 
BLM and Rad51 protein co-expression in breast cancer: A key interacting partner of 
BLM is Rad51 (24). Together BLM-Rad51 play an essential role in HR repair (1-5). We 
therefore conducted exploratory nuclear co-expression studies in breast cancer.  As shown in 
supplementary Table S7, we observed significant association between BLM-/Rad51- tumours 
and NPI>3.4, high grade, high mitotic index, pleomorphism, tumour type, ER- and PR- 
tumours.  
 
Survival analyses: In univariate analysis, in high risk ER positive tumours that received no 
endocrine therapy, patients whose tumours had high nuclear/low cytoplasmic BLM had poor 
breast cancer specific survival (p=0.036) implying that altered expression has prognostic 
significance (Supplementary Figure S3). In patients who received endocrine therapy, 
although low nuclear/high cytoplasmic BLM tumours have the worst survival, there was no 
statistical significance. Similarly in ER- tumours, BLM level did not significantly influence 
survival. When BLM (nuclear) and Rad51 (nuclear) were investigated together, BLM-
/Rad51- tumours have poor survival in the whole cohort and in the ER- sub-group that 
received adjuvant chemotherapy (Supplementary Figure S4). BLM/Rad51 expression did not 
influence survival in ER + tumours (Supplementary Figure S5). In multivariate analysis 
(Supplementary Table S8), nuclear BLM level independently influenced survival (p=0.026). 
Tumour stage, grade and HER-2 expression were other factors independently associated with 
breast cancer specific survival.    
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DISCUSSION 
 
This is the first and the largest study to evaluate BLM in sporadic breast cancers.  We provide 
compelling evidence that high BLM mRNA expression is a strong prognostic and predictive 
biomarker in breast cancer. High BLM mRNA was linked to aggressive clinicopathological 
phenotypes. High BLM mRNA was associated with aggressive molecular phenotypes 
including PAM50. Luminal B, PAM50. Her2 and PAM50. basal molecular phenotypes. 
Given the role of BLM during replication and proliferation (25), it is perhaps not surprising 
that high BLM mRNA was more frequent in aggressive breast cancers. To further support this 
hypothesis we also observed that low BLM mRNA expression was more common in PAM50. 
Lumina A and ER+/Her-2 negative/low proliferation Genefu subtype tumours. Interestingly, 
BLM mRNA levels are also linked to biologically distinct integrative clusters reported in the 
METABRIC study (11). High BLM mRNA level was frequent in intClust 10 subgroup which 
is the most highly genomically instable sub group with basal-like features.  Low BLM  
mRNA level was seen in intClust 3 subgroup that is characterised by low genomic instability. 
Together the data suggest that BLM mRNA level may also inform genomic stability status in 
breast. In addition, high BLM mRNA level is also frequently seen in intClust 5 (HER-2 
enriched with worst survival), intClust 9 (8q cis-acting/20qamplified mixed subgroup), and 
intClust 1 (17q23/20q cis-acting luminal B subgroup) subgroups that also manifest an 
aggressive phenotype. On the other hand, low BLM mRNA level is linked to  intClust 4 
(includes both ER-positive and ER-negative cases with a flat copy number landscape and 
termed the ‘CNA-devoid’ subgroup with extensive lymphocytic infiltration), intClust 7 (16p 
gain/16q loss with higher frequencies of 8q amplification luminal A subgroup) and intClust 8 
subgroups (classical 1q gain/16q loss luminal A subgroup) (11). Of note, the data presented 
here is strikingly similar to the clinicopathological associations we recently reported for 
16 
 
FEN1 (flap endonuclease 1), a key player in long-patch base excision repair and DNA 
replication, in the METABRIC cohort. Interestingly, BLM has been shown to stimulate 
FEN1 activity in a preclinical study (26). The functional interaction appeared to be 
independent of BLM helicase activity in that study (26).  
 
At the protein level, low nuclear and/or high cytoplasmic expression was associated with 
aggressive phenotypes. Association with high cytoplasmic expression was surprising.  As 
cytoplasmic function of BLM has not been described previously, we speculate that 
cytoplasmic accumulation in a proportion of breast tumours probably reflects dysregulation 
of mechanisms involved in nuclear localization of BLM.  Cytoplasmic accumulation along 
with low nuclear BLM expression could then increase genomic instability in tumours and 
promote a mutator phenotype characterised by aggressive biology. To support this hypothesis 
we also observed that high cytoplasmic/low nuclear BLM levels were more likely to be high 
grade, high mitotic index, pleomorphism, IDC-NST tumour type, PR-, triple negative and 
basal-like phenotype tumours. In addition, low nuclear BLM was associated with impaired 
expression of other DNA repair factors including BRCA1 negativity, low XRCC1, low 
FEN1, low SMUG1, low APE1, low Polβ, low ATR and low DNA-PKcs. Moreover, in 
multivariate analysis, nuclear BLM level independently influenced survival. As BLM and 
Rad51 are known to interact with each other for efficient HR repair (24), we also performed 
BLM-Rad51 co-expression studies. As expected, low nuclear BLM/low nuclear RAD51 
tumours exhibited aggressive phenotype and associated with poor survival.   In a previous 
small study in normal and neoplastic human cells, BLM protein expression was shown to be 
overexpressed in a panel of tumour tissue compared to normal tissue including a cohort of 
nine breast tumours (27). Similar to our study, the authors observed a positive correlation 
between BLM and Ki67 but did not report any clinicopathological associations (27). Another 
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interesting observation in the current study was that although BLM mRNA overexpression 
was categorically associated with aggressive tumours and poor outcomes, at the protein level, 
the association appeared more complex with low nuclear BLM protein level or low 
nuclear/high cytoplasmic BLM protein level being associated with adverse features. We 
speculate that either BLM mRNA is subjected to post-transcriptional regulation or post 
translational dysregulation of BLM protein expression/sub-cellular localization could in turn 
affect BLM mRNA expression through feedback loops. Detailed mechanistic studies are 
therefore required to understand the regulation of BLM in vivo.  Data presented in the current 
study also suggest that BLM could be a promising marker for personalization of therapy. As 
low BLM is a marker of impaired HR repair, we would argue that low BLM tumours could 
be targeted by synthetic lethality using inhibitors of base excision repair such as those 
targeting PARP (28). Alternatively high BLM tumours could be targeted by small molecular 
inhibitors of BLM that are currently under development (10). In conclusion we provide the 
first clinical evidence that BLM is a promising biomarker and a rational drug target in breast 
cancer. 
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Table 1: Association between BLM mRNA expression and clinico-pathologic variables in 
METABRIC cohort (N=1950). 
 
 
Variable 
 
 
BLM mRNA Expression 
 
 
 P Values 
Low High 
Unadjusted Adjusted* 
N (%) N (%) 
 
A) Pathological    Parameters
Lymph node stage  
Negative 434(56.9%) 601(49.8%) 0.003 
 
0.0034 
 Positive (1-3) 100(13.1%) 214(17.7%) 
Positive (>3) 229(30.0%) 393(32.5%) 
Grade 
G1 124(17.3%) 45(3.8%) 1.9X10-63 1.0X10-5 
G2 404(56.3%) 366(31.3%) 
G3 190(26.5%) 760(64.9%) 
Tumour Size (cm) 
T 1a+b(1.0) 49(6.4%) 43(3.6%) 1.4X10-5 1.0X10-5 
T 1c(>1.0-2.0) 334(43.9%) 432(36.1%) 
T2 (>2.0-5) 341(44.9%) 660(55.1%) 
T3 (>5) 36(4.7%) 62(5.2%)
NPI 
≤ 3.4 385(50.3%) 295(24.3%) 2.2X10-32 1.0X10-5 
>3.4 380(49.7%) 917(75.7%) 
 
Her2 overexpression (No)  733(95.8%) 999(82.4%) 1.3X10-18 1.0X10-5 
                                  (Yes ) 32(4.2%) 213(17.6%) 
Triple negative          (No)      731(95.6) 929 (76.7) 6.5X10-29 1.0X10-5 
                                  (Yes)  34(4.4) 283(23.3) 
ER                       (Negative) 55(7.2%) 415(34.2%) 4.3X10-43 1.0X10-5
                            (Positive) 710(92.8%)  797(65.8%) 
PgR                     (Negative) 223(29.2%) 713(58.8%) 6.4X10-38 1.0X10-5 
                            (Positive) 542(70.8%) 499(41.2%) 
Genefu subtype 
ER-/Her-2 negative 20(5.1%) 130(21.5%) 2.2X10-12 1.0X10-5
ER+/Her-2 negative/high 
proliferation 71(18.3%) 295(48.8%) 
2.2X10-22 1.0X10-5 
ER+/Her-2 negative/low 
proliferation 283(72.8%) 85(14.0%) 
4.4X10-78 1.0X10-5 
Her-2 positive 15(3.9%) 95(15.7%) 6.2X10-9 1.0X10-5
22 
 
PAM50 subtype 
PAM50.Her2 33(5.2%) 205(18.0%) 3.8X10-14 1.0X10-5 
PAM50.Basal   19(3.0%) 311(27.3%)  2.2X10-36 1.0X10-5
PAM50.LumA 483(76.2%) 232(20.4%)  8.1X10-117 1.0X10-5
PAM50.LumB 98(15.5%) 391(34.3%) 1.7X10-17 1.0X10-5
IntClust subgroups 
intClust.1 21(2.7%) 116(9.6%) 5.8X10-9 1.0X10-5 
intClust.2 20(2.6%) 52(4.3%) 0.053 0.055 
intClust.3  203(26.5%) 87(7.2%) 2.1X10-32 1.0X10-5
intClust.4 191(25.0%) 152(12.5%) 1.2X10-12 1.0X10-5
intClust.5 21(2.7%) 168(13.9%) 2.6X10-16 1.0X10-5
intClust.6 27(3.5%) 59(4.9%) 0.155 4.03 
intClust.7 92(12.0%) 97(8.0%) 0.003 0.003 
intClust.8 156(20.4) 144(11.9%) 2.7X10-7 1.0X10-5
intClust.9 28(3.7%) 118(9.7%)   4.8X10-7 1.0X10-5
intClust.10 6(0.8%) 219(18.1%) 4.5X10-32 1.0X10-5
Bold = Statistically significant; HER2: human epidermal growth factor receptor 2; ER: 
oestrogen receptor; PgR: progesterone receptor;Triple negative: ER-/PgR-/HER2-. *Adjusted 
p values were calculated using Benjamini-Hochberg method to adjust for multiple testing. 
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Table 2: Multivariate analysis in the METABRIC cohort confirms that BLM mRNA over 
expression is a powerful independent prognostic factor. 
 P-Value HR 95% CI for HR 
Lower Upper 
Breast Cancer Specific Survival 
BLM mRNA expression 2.0x10-6 1.523 1.278 1.815 
Size  1.0x10-6 1.112 1.068 1.158 
Grade 
G1 
G2 
G3 
 
 
0.121 
0.0044 
 
1.0 
1.782 
2.03 
 
 
1.094 
1.241 
 
 
2.903 
3.321 
LN Status 
LN (1-3) 
LN(>3) 
 
0.21 
1.0x10-6 
 
1.697 
3.646 
 
1.367 
2.890 
 
2.108 
4.601 
 
Bold: Statistically significant; HR: Hazard Ratio; CI: Confidence interval; LN: Lymph node 
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Table 3. BLM (nuclear and cytoplasmic protein co-expression) in breast cancer (n=1253)  
  
   
 
                    VARIABLE 
 
BLM  Protein Expression 
 
 
 
P- value 
 
 
 
*P -Value 
(Adjusted) Nuc-/Cyto- 
 
N (%) 
Nuc+/Cyto- 
 
N (%) 
Nuc/Cyto+ 
 
N (%) 
Nuc+/Cyto+ 
 
N (%) 
A) Pathological    Parametersic 
Tumour Size  
 <1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
 29 (8.7) 
163 (49.1) 
127 (38.3) 
13 (3.9) 
 
30 (12.6) 
111 (46.6) 
92 (38.7) 
5 (2.1) 
 
21 (6.0) 
182 (52.0) 
138 (39.4) 
9 (2.6) 
 
37 (11.1) 
172 (51.7) 
121 (36.3) 
3 (0.9) 
 
0.065 
 
0.083 
Tumour Stage                             
1 
2 
3 
 
 
207 (62.3) 
92 (27.7) 
33 (9.9) 
 
153 (64.0) 
66 (27.6) 
20 (8.4) 
 
215 (61.3) 
106 (30.2) 
30 (8.5) 
 
203 (61.0) 
102 (30.6) 
28 (8.4) 
 
0.946 
 
39.73 
Tumour Grade                           
 G1 
 G2 
 G3 
  
 
53 (16.0) 
87 (26.2) 
192 (57.8) 
 
52 (21.8) 
208 (42.0) 
86 (36.1) 
 
45 (12.9) 
102 (29.1) 
203 (58.0) 
 
59 (17.7) 
108 (32.4) 
166 (49.8) 
 
3.0X10-6 
 
1.0X10-5 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
M3 (high; mitosis >18) 
 
93 (28.4) 
65 (19.8) 
170 (51.8) 
  
117 (49.4) 
39 (16.5) 
81 (34.2) 
 
91 (26.1) 
64 (18.3) 
194 (55.6) 
 
129 (38.9) 
55 (16.6) 
148 (44.6) 
 
1.0X10-6 
 
1.0X10-5 
Tubule Formation                      
1 (>75% definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
 
17 (5.2) 
107 (32.6) 
204 (62.2) 
 
14 (5.9) 
83 (35.0) 
140 (59.1) 
 
17 (4.9) 
112 (32.1) 
220 (63.0) 
 
20 (6.0) 
118 (35.5) 
194 (58.4) 
 
0.90 
 
0.92 
Pleomorphism                             
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
12 (3.7) 
112 (34.1) 
204 (62.2) 
 
6 (2.5) 
122 (51.5) 
109 (46.0) 
 
2 (0.6) 
119 (34.2) 
227 (65.2) 
 
8 (2.4) 
114 (34.4) 
209 (63.1) 
 
1.2X10-5 
 
1.0X10-5 
Tumour Type                
IDC-NST 
Tubular Carcinoma 
Medullary Carcinoma 
ILC 
Others 
 
170 (59.2) 
55 (19.2) 
12 (4.2) 
28 (9.8) 
22 (7.7) 
 
105 (53.3) 
39 (19.8) 
0 (0.0) 
30 (15.2) 
23 (11.7) 
 
204 (65.2) 
59 (18.8) 
12 (3.8) 
17 (5.4) 
21 (6.7) 
 
170 (58.2) 
66 (22.6) 
3 (1.0) 
18 (6.2) 
35 (12.0) 
 
6.6X10-5 
 
1.0X10-4 
Lymphovascular Invasion         
No 
Yes 
 
219 (67.2) 
107 (32.8) 
 
144 (62.1) 
88 (37.9) 
 
235 (67.9) 
111 (32.1) 
 
218 (65.3) 
116 (34.7) 
 
0.486 
 
0.551 
B) Aggressive phenotype 
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Her2 overexpression                  
No 
Yes 
 
290 (89.2) 
35 (10.8) 
 
205 (88.4) 
27 (11.6) 
 
313 (90.5) 
33 (9.5) 
 
282 (87.3) 
41 (12.7) 
 
0.617 
 
0.664 
Triple Negative Phenotype        
No 
Yes 
 
244 (74.8) 
82 (25.2) 
 
210 (89.4) 
25 (10.6) 
 
248 (73.2) 
91 (26.8) 
 
285 (88.5) 
37 (11.5) 
 
1.0X10-6 
 
1.0X10-5 
Basal Like Phenotype           
No 
Yes 
 
260 (83.3) 
52 (16.7) 
 
216 (93.9) 
14 (6.1) 
 
267 (82.2) 
58 (17.8) 
 
 
287 (90.5) 
30 (9.5) 
 
2.9X10-5 
 
1.0X10-4 
Cytokeratin 6 (CK6)                  
Negative 
Positive 
 
223 (79.6) 
57 (20.4) 
 
168 (88.9) 
21 (11.1) 
 
252 (81.0) 
59 (19.0) 
 
 
248 (87.6) 
35 (12.4) 
 
0.007 
 
0.011 
Cytokeratin 14 (CK14)              
Negative 
Positive 
 
233 (84.1) 
44 (15.9) 
 
163 (88.1) 
22 (11.9) 
 
266 (86.4) 
42 (13.6) 
 
256 (90.8) 
26 (9.2) 
 
0.114 
 
0.141 
Cytokeratin 18 (CK18)              
Negative 
Positive 
 
49 (18.6) 
215 (81.4) 
 
 
6 (3.4) 
170 (96.6) 
 
35 (12.5) 
245 (87.5) 
 
13 (5.1) 
241 (94.9) 
 
1.0X10-6 
 
1.0X10-5 
Cytokeratin 19 (CK19)              
Negative 
Positive 
 
29 (10.2) 
254 (89.8) 
 
6 (3.2) 
182 (96.8) 
 
17 (5.5) 
291 (94.5) 
 
14 (5.0) 
264 (95.0) 
 
0.008 
 
0.012 
C) Hormone receptors 
 
 
ER               
Negative 
Positive 
 
110 (33.5) 
218 (66.5) 
 
40 (16.9) 
197 (83.1) 
 
112 (32.7) 
231 (67.3) 
 
68 (20.6) 
262 (79.4) 
 
1.0X10-6 
 
1.0X10-5 
PgR                                   
Negative 
Positive 
 
151 (47.6) 
166 (52.4) 
 
87 (39.4) 
134 (60.6) 
 
156 (48.0) 
169 (52.0) 
 
115 (37.8) 
189 (62.2) 
 
0.016 
 
0.022 
AR                     
Negative 
Positive 
 
 
126 (47.0) 
142 (53.0) 
 
44 (25.0) 
316 (75.0) 
 
122 (42.2) 
167 (57.6) 
 
79 (30.0) 
184 (70.0) 
 
1.0X10-6 
 
1.0X10-5 
D) DNA Repai 
 
BRCA1                     
Absent 
 Normal 
 
59 (24.6) 
181 (75.4) 
 
20 (13.2) 
131 (86.8) 
 
52 (20.3) 
204 (79.7) 
 
41 (17.3) 
196 (82.7) 
 
 
0.036 
 
0.047 
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XRCC1                             
Low 
High 
 
61 (25.6) 
177 (74.4) 
 
23 (12.8) 
156 (87.2) 
 
27 (11.6) 
205 (88.4) 
 
153 (16.7) 
761 (83.3) 
 
1.7X10-4 
 
3.0X10-4 
FEN1                   
Low 
High 
 
192 (83.8) 
37 (16.2) 
 
117 (69.6) 
51 (30.4) 
 
169 (74.1) 
59 (25.9) 
 
152 (65.8) 
79 (34.2) 
 
1.0X10-4 
 
2.0X10-4 
SMUG1                  
Low 
High 
 
 
104 (47.1) 
117 (52.9) 
 
 
51 (33.3) 
102 (66.7) 
 
73 (34.4) 
139 (65.6) 
 
77 (35.5) 
140 (64.5) 
 
0.013 
 
0.018 
APE1 
Low 
High 
 
185 (66.8) 
92 (33.2) 
 
93 (44.7) 
115 (55.3) 
 
99 (35.0) 
184 (65.0) 
 
532 (49.7) 
538 (50.3) 
 
1.0X10-6 
 
1.0X10-5 
Polβ 
Low 
High 
 
 
147 (50.9) 
142 (49.1) 
 
56 (25.9) 
160 (74.1) 
 
130 (42.1) 
179 (57.9) 
 
91 (30.6) 
206 (69.4) 
 
1.0X10-6 
 
1.0X10-5 
ATR 
Low 
High 
 
236 (75.9) 
75 (24.1) 
 
146 (69.5) 
64 (30.5) 
 
221 (67.4) 
107 (32.6) 
 
175 (55.6) 
140 (44.4) 
 
1.0X10-6 
 
1.0X10-5 
ATM 
Low 
High 
 
109 (54.0) 
93 (46.0) 
 
73 (52.5) 
66 (47.5) 
 
114 (50.2) 
113 (49.8) 
 
106 (54.6) 
88 (45.4) 
 
0.806 
 
0.846 
DNA-PKcs 
Low 
High 
 
126 (45.8) 
149 (54.2) 
 
58 (29.4) 
139 (70.6) 
 
124 (41.5) 
175 (58.5) 
 
68 (23.3) 
224 (76.7) 
 
1.0X10-6 
 
1.0X10-5 
E) Cell cycle/apoptosis regulators 
 
 
P16 
Low 
High 
 
199 (81.9) 
44 (18.1) 
 
139 (93.9) 
9 (6.1) 
 
197 (79.8) 
50 (20.2) 
 
208 (93.7) 
14 (6.3) 
 
 
1.0X10-6 
 
1.0X10-5 
P21 
Low 
High 
 
151 (59.4) 
103 (40.6) 
 
84 (54.2) 
71 (45.8) 
 
165 (61.6) 
103 (38.4) 
 
118 (52.4) 
107 (47.6) 
 
0.154 
 
0.184 
MIB1                       
Low 
High 
 
121 (44.5) 
151 (55.5) 
 
117 (57.6) 
86 (42.4) 
 
106 (37.7) 
175 (62.3) 
 
127 (44.9) 
156 (55.1) 
 
 
4.2X10-5 
 
1.0X10-4 
P53              
Low expression 
High expression 
           
 
214 (78.1) 
60 (21.9) 
 
156 (85.2) 
27 (14.8) 
 
206 (72.0) 
80 (28.0) 
 
225 (80.9) 
53 (19.1) 
 
0.005 
 
0.008 
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Bcl-2                            
Negative 
Positive 
 
119 (40.3) 
176 (59.7) 
 
56 (27.5) 
148 (72.5) 
 
127 (27.5) 
148 (72.5) 
 
99 (32.8) 
203 (67.2) 
 
 
0.006 
 
0.009 
TOP2A                    
Low 
Overexpression 
 
 
129 (56.6) 
99 (43.4) 
 
64 (39.8) 
97 (60.2) 
 
110 (43.1) 
145 (56.9) 
 
98 (41.4) 
139 (58.6) 
 
0.001 
 
0.002 
pCHK1 (Nuclear)                       
Low 
High 
 
298 (90.0) 
33 (10.0) 
 
160 (66.7) 
80 (33.3) 
 
318 (90.3) 
34 (9.7) 
 
255 (76.3) 
79 (23.7) 
 
1.0X10-6 
 
1.0X10-5 
pCHK1 (Cytoplasmic)               
Low 
High 
 
123 (37.2) 
208 (62.8) 
 
64 (26.7) 
176 (73.3) 
 
68 (19.3) 
284 (80.7) 
 
60 (18.0) 
274 (82.0) 
 
1.0X10-6 
 
1.0X10-5 
Non-phospho CHK1                   
Low 
High 
 
151 (57.0) 
114 (43.0) 
 
92 (50.0) 
92 (50.0) 
 
133 (47.3) 
148 (52.7) 
 
113 (41.9) 
157 (58.1) 
 
0.005 
 
0.008 
CHK2                       
Low 
High 
 
145 (59.7) 
98 (40.3) 
 
72 (45.6) 
86 (54.4) 
 
113 (42.2) 
155 (57.8) 
 
92 (38.0) 
150 (62.0) 
 
9.0X10-6 
 
1.0X10-5 
Bax                         
Low 
High 
 
138 (75.4) 
123 (24.6) 
 
99 (76.7) 
30 (23.3) 
 
134 (63.2) 
78 (36.8) 
 
136 (69.0) 
61 (31.0) 
 
0.018 
 
0.024 
CDK1                            
Low 
High 
 
 
142 (68.3) 
66 (31.7) 
 
98 (74.2) 
34 (25.8) 
 
161 (66.3) 
82 (33.7) 
 
149 (70.6) 
62 (29.4) 
 
0.416 
 
0.485 
CDK18 (Cytoplasmic)                
Low 
High 
 
223 (84.8) 
40 (15.2) 
 
144 (77.4) 
42 (22.6) 
 
203 (72.5) 
77 (27.5) 
 
174 (65.9) 
90 (34.1) 
 
7.0X10-6 
 
1.0X10-5 
RECQL5                  
Low 
High 
 
161 (63.6) 
92 (36.4) 
 
74 (39.8) 
112 (60.2) 
 
134 (48.9) 
140 (51.1) 
 
93 (35.0) 
173 (65.0) 
 
1.0X10-6 
 
1.0X10-5 
MDM2                          
Low 
Overexpression 
 
184 (76.3) 
57 (23.7) 
 
112 (73.2) 
41 (26.8) 
 
202 (78.3) 
56 (21.7) 
 
160 (73.4) 
58 (26.6) 
 
0.544 
 
0.601 
Bold = statistically significant; BRCA1: Breast cancer 1, early onset; HER2: human 
epidermal growth factor receptor 2; ER: oestrogen receptor; PgR: progesterone receptor; CK: 
cytokeratin; Basal-like: ER-, HER2 and positive expression of either CK5/6, CK14 or EGFR; 
Triple negative: ER-/PgR-/HER2- . Adjusted p values were calculated using Benjamini-
Hochberg false discovery rate method to adjust for multple testing. *Fischer test was used to 
obtain p values where one or more of cells has an expected frequency of five or less. 
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FIGURE LEGENDS 
                                                                                                                                                                   
Figure 1: Kaplan Meier curves showing BCSS (Breast cancer specific survival) based on 
BLM mRNA expression in A. whole cohort; B. ER+ cohort; C. ER- cohort; D. ER+ patients 
with NPI >3.4, who received endocrine therapy and E. ER- patients with NPI >3.4, who 
received chemotherapy. 
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